Healthcare / BiotechnologyNasdaqCM
$7.35
-0.25 (-3.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-28.6M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$196M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-87.9%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-26.6M · FCF $-31.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | $675000.00 | $951000.00 | — | — |
| Net Income | $-26.6M | $-26.6M | $-36.7M | $-30.5M | $-18.1M | $-10.0M | $-2.3M |
| EBITDA | $-25.9M | $-25.9M | $-36.2M | $-30.2M | $-17.9M | $-8.5M | — |
| EPS | -1.67 | -1.67 | -5.65 | -12.80 | -12.00 | -8.60 | -2.70 |
| Operating Margin | — | — | — | -3077.6% | -1898.2% | — | — |
| Net Margin | — | — | — | -4525.0% | -1898.8% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.10 | -0.21 | -0.43 | — | — |
| Current Ratio | 2.40 | 2.40 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-31.3M | $-31.3M | $-28.6M | $-18.3M | $-15.7M | $-5.8M | — |
| Returns | |||||||
| ROE | -87.9% | -87.9% | -494.3% | 801.9% | 3875.1% | -60.8% | 84.8% |
| Valuation | |||||||
| P/B | 3.87 | 3.87 | 7.02 | — | — | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | -29.0% | — | — | — |
| EPS Growth | 70.4% | 70.4% | 55.9% | -6.7% | — | -218.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.65 → -1.67
Residual
+11.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.